What is driving Oxford BioMedica’s revenue growth?

Revenue growth is primarily driven by increasing contracted orders in cell and gene therapy manufacturing and expanded production capacity.

How does EQT’s bid affect the market?

The EQT bid overhang influences investor sentiment and trading dynamics, as the market awaits the decision on the potential takeover.

What is the company’s financial position?

Oxford BioMedica maintains a strong cash position, supporting operational flexibility and investment in manufacturing facilities.

Oxford BioMedica (LSE:OXB) Shares Drop Ahead of EQT Deadline

FTSE 100 OAP3

3 min read | February 24, 2026 11:10 PM AEDT | By Vivek Singh

Google News:

Oxford BioMedica (LSE:OXB) Shares Drop Ahead of EQT Deadline — Image source: Shutterstock

Strong Full-Year Performance by Oxford BioMedica

Oxford BioMedica (OXB) recently released its full-year trading update, capturing attention across the LSE & FTSE stock market. Despite delivering solid results, shares experienced a notable decline as investors remain focused on the private equity interest from EQT. The company’s full-year revenues reached the top end of guidance, reflecting healthy growth in its cell and gene therapy contract manufacturing operations.

The trading update highlighted progress in operational performance, with underlying EBITDA improving from the previous year, supported by the recent acquisition of a viral vector manufacturing facility in North Carolina. Excluding one-off gains, the core business remains on an upward trajectory, signaling steady growth.

Contract Manufacturing Strength and Order Backlog

A critical driver of Oxford BioMedica’s (LSE:OXB) performance has been the rise in contracted client orders, which saw a substantial increase, boosting the company’s revenue backlog. This extended visibility provides confidence in operational planning and sets a strong foundation for the upcoming year. Companies operating in the contract development and manufacturing organization (CDMO) sector are closely watching this trend, given its importance for long-term revenue predictability.

The company’s cash position remains solid, providing financial flexibility for strategic initiatives and continued investment in advanced manufacturing capabilities. This strong liquidity position has been viewed positively by market participants, especially as the private equity interest from EQT continues to influence market sentiment.

EQT Bid Overhang Influences Market

The looming deadline for EQT’s decision has become a focal point for investors. Shares of Oxford BioMedica (LSE:OXB) had previously re-rated as speculation around EQT’s bid emerged. With the deadline approaching, the market is closely observing whether EQT proceeds with the offer or withdraws, which could redefine share valuation.

Market commentary suggests that while Oxford BioMedica is trading in line with its sector peers on an EV/Sales basis, the premium associated with a takeover bid has not yet been fully reflected. This overhang continues to influence trading dynamics and investor sentiment in the FTSE 100 shares price space.

Sector Comparisons and Valuation

Oxford BioMedica’s (LSE:OXB) performance can also be contextualized within the broader FTSE 100 and FTSE 350 indices. Comparisons within the CDMO segment show that the company is maintaining healthy growth metrics, with order intake and backlog trends providing visibility that aligns with sector expectations.

Contracted client commitments and cash reserves reinforce the company’s strategic position, making it a notable contender among FTSE AIM 50 listed stocks. Investors are closely monitoring the upcoming developments surrounding EQT’s bid, which will likely influence share performance across these indices.

Future Outlook and Strategic Implications

Looking ahead, Oxford BioMedica’s (LSE:OXB) growth is expected to be supported by its expanding manufacturing capacity and strong client demand. The successful integration of the North Carolina facility is anticipated to enhance production capabilities and operational efficiency. Market attention will also remain on EQT’s decision, as any bid outcome could significantly impact investor sentiment.

The company’s focus on cell and gene therapy manufacturing positions it in a high-growth sector, with continued demand expected from pharmaceutical and biotech partners. This positions Oxford BioMedica to capitalize on sector trends while maintaining resilience against market volatility.

Frequently Asked Questions

What is driving Oxford BioMedica’s revenue growth?

Revenue growth is primarily driven by increasing contracted orders in cell and gene therapy manufacturing and expanded production capacity.
How does EQT’s bid affect the market?

The EQT bid overhang influences investor sentiment and trading dynamics, as the market awaits the decision on the potential takeover.
What is the company’s financial position?

Oxford BioMedica maintains a strong cash position, supporting operational flexibility and investment in manufacturing facilities.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.